Medical Advocates
Ethics and Infectious Diseases
  Ethical Challenges
Screening/Testing
 Refusal of Care/Services
Detention
Patient Exploitation
Compulsory Treatment
Decision-Making
Reproduction
Transplants
End-of-Life Care
Enteral Nutrition
Professional Associations
National Challenges         Sterilization
Bioterrorism                     Prison Challenges
 HIV Exceptionalism           Conflicts of Interest
Pharmaceutical Industry   Pregnancy
HIV Prevention   
Stigma
 Physician Reimbursement 
Ethics and Disease Challenges and Duties
 HIV Cure
 Ebola Virus Disease
 Executions






 
Ethics Main Page Main New and Noteworthy Home Page

Medical Advocates
Enfuvirtide [T-20] (Fuzeon)
 
Conference Citations

14th CROI
8th Int Congress on Drug Therapy in HIV Infection
46th ICAAC
XVI International AIDS Conference
13th CROI
45th ICAAC
 3rd IAS Conference
 6th Int Wkshp on Clinical Pharmacology of HIV Therapy
12th CROI
44th ICAAC
 XV International AIDS Conference
 Conference Archives
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
Last Update:  February 26, 2008
14th Conference on Retroviruses and
Opportunistic Infections
  • CONFERENCE PDF POSTER
         Enfuvirtide Does Not Require Dose-adjustment in Patients with Chronic Renal Failure: The Results
    of a Pharmacokinetic Study of Enfuvirtide in HIV-1-infected Patients with Impaired Renal Function
    (NP17586)
    P Tebas, N Bellos, C Lucasti, et al
     PDF Poster    Abstract
  • CONFERENCE PDF POSTER
         Lack of Placental Transfer of Enfuvirtide in an ex vivo Human Placental Cotyledon Perfusion Model
         Ferreira, P Ceccaldi, B Visseaux, et al
         PDF Poster    Abstract
  • CONFERENCE PDF POSTER
         CCR5 Density Levels on Primary CD4 T Cells Affect the Replication and Enfuvirtide Susceptibility of
    R5 HIV-1: Clinical Implications
         A Heredia, B Gilliam, O Latinovic, et al
         PDF Poster    Abstract
  • CONFERENCE PDF POSTER
         Kinetics of Disappearance of Enfuvirtide-resistance HIV-1 Mutations after Drug Discontinuation
         C Charpentier, M Jenabian, C Piketty, et al
    PDF Poster        Abstract
8th Int Congress on Drug Therapy in HIV Infection
 
  • A pilot 48 week study of once daily (180mg QD) vs twice daily (90mg BID) enfuvirtide (ENF)
         D Wright, A Rodriguez, E Godofsky, et al
         Abstract
  • Injection site reactions (ISR) and success of HAART influence continued use of enfuvirtide (T20)
         M Vogel, E Wolf, K Ummard, et al
         Prospective study assessing injection site reactions, quality of life and enfuvirtide administration
    preference using Biojector versus needles
         M Loutfy, M Harris, J Raboud, et al
         Enfuvirtide + NRTIs for the treatment of HIV infected patients with concurrent active mycobacterial
    infection: a pilot experience
         C Allavena, C Biron, M-P Cossevin, et al
     Inter-country variation in physician perspectives of enfuvirtide (ENF) prescribing
         R Horne, V Cooper, G Gellaitry
    Abstract
  • Switching a toxicity-causing antiretroviral (ARV) to enfuvirtide (ENF) in patients with treatment-
    limiting toxicities
     M Stoll, M Muller, S Staszewski, et al
         Abstract
  • Mitochondrial DNA (mtDNA) content in enfuvirtide-treated healthy volunteers
         G Garrabou, S Lopez, V Rodriguez, et al
     Abstract
  • Friends of Fuzeon
         KF MacRae
    Abstract
XVI International AIDS Conference
 
  • The mechanism of enfuvirtide resistance and structural insights into the corresponding fitness deficits
    in response to the N43D resistance mutation
    Bai X., Seedorff J., Wilson K., et a    l
    Abstract